Results

Merck & Co. Inc.

06/24/2022 | Press release | Distributed by Public on 06/24/2022 04:53

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following[...]